While CureVac N.V. has overperformed by 3.74%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CVAC fell by -55.54%, with highs and lows ranging from $12.36 to $2.93, whereas the simple moving average fell by -53.15% in the last 200 days.
On June 08, 2023, SVB Securities started tracking CureVac N.V. (NASDAQ: CVAC) recommending Outperform. A report published by UBS on January 19, 2023, Upgraded its rating to ‘Buy’ for CVAC. Jefferies also Upgraded CVAC shares as ‘Buy’, setting a target price of $21 on the company’s shares in a report dated January 09, 2023. BofA Securities January 21, 2022d the rating to Underperform on January 21, 2022, and set its price target from $55 to $20. JMP Securities initiated its ‘Mkt Outperform’ rating for CVAC, as published in its report on January 18, 2022. Deutsche Bank’s report from October 22, 2021 suggests a price prediction of $35 for CVAC shares, giving the stock a ‘Hold’ rating. BofA Securities also rated the stock as ‘Neutral’.
Analysis of CureVac N.V. (CVAC)
Further, the quarter-over-quarter increase in sales is 58.86%, showing a positive trend in the upcoming months.
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of CureVac N.V.’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of -51.09% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 3.41, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and CVAC is recording an average volume of 967.22K. On a monthly basis, the volatility of the stock is set at 5.04%, whereas on a weekly basis, it is put at 6.53%, with a loss of -9.50% over the past seven days. Furthermore, long-term investors anticipate a median target price of $12.89, showing growth from the present price of $3.05, which can serve as yet another indication of whether CVAC is worth investing in or should be passed over.
How Do You Analyze CureVac N.V. Shares?
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 59.08%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 10.02% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
CVAC shares are owned by institutional investors to the tune of 10.02% at present.
